share_log

百利天恒(688506.SH):注射用BL-M14D1(ADC)项目治疗晚期实体瘤获得I期临床试验批准通知书

Bailitianheng (688506.SH): Injection use of BL-M14D1 (ADC) project for the treatment of advanced solid tumors has obtained the Phase I clinical trial approval notice.

Gelonghui Finance ·  Jul 11 06:40

On July 11th, Gelunhui reported that Baili Tianheng (688506.SH) recently received the "Drug Clinical Trial Approval Notice" officially issued by the National Medical Products Administration (NMPA). The clinical trial of the company's independently developed innovative biological drug BL-M14D1 (ADC) has been approved. BL-M14D1 is an ADC drug that shares the same "linker + toxin" platform as BL-B01D1, both of which are derived from the same small molecule technology platform. Its indication is late-stage solid tumors.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment